No Data
No Data
Wells Fargo Upgrades Travere Therapeutic(TVTX.US) to Buy Rating, Announces Target Price $27
Wells Fargo Upgrades Travere Therapeutics to Overweight From Equalweight, Adjusts Price Target to $27 From $9
12 Health Care Stocks Moving In Thursday's After-Market Session
Sector Update: Health Care Stocks Flat to Lower Pre-Bell Thursday
Travere Therapeutics Receives Swiss Regulator's Temporary Marketing Approval for Kidney Disease Treatment
Express News | CSL Vifor and Travere Therapeutics Announce Swissmedic Approval of Filspari® (Sparsentan) for the Treatment of Iga Nephropathy